Immuron Limited (IMC)

Overview

Immuron Limited, established in 1994 and based in Carlton, Australia, is a pioneering biopharmaceutical entity actively involved in the research, development, and global commercialization of polyclonal antibodies. With its operations spread across Australia, Israel, Canada, the United States, and other international markets, the company is segmented into two critical divisions: Research and Development, and Hyperimmune Products. Immuron has forged essential research alliances with reputable institutions like the Naval Medical Research Center and the Walter Reed Army Institute of Research, aiming to develop innovative therapies for infections caused by Campylobacter, enterotoxigenic Escherichia coli, and shigellosis.

Products and Services

Immuron Limited offers a diverse array of products and services highlighted by its focus on immune supplements and the development of treatments for gastrointestinal ailments and infections:

• Travelan: This over-the-counter medicine is designed to minimize the risk of travelers' diarrhea and other minor gastrointestinal disorders. Additionally, it serves as a dietary supplement that supports digestive health and provides protection for the gastrointestinal tract. Its development for use in preventing travelers' diarrhea in the United States signifies Immuron's commitment to combating this common ailment.
• Protectyn: Another significant product, Protectyn, is an immune supplement formulated to aid in maintaining wholesome digestive functions and liver health. It exemplifies Immuron's dedication to leveraging its expertise in polyclonal antibodies for enhancing general health and well-being.
• IMM-124E (Travelan in the US): Currently under development to offer protection against contracting travelers' diarrhea in the United States, this marks a significant stride in Immuron's product pipeline. It highlights the company's efforts to address the broader international market needs.
• IMM-529 for Clostridium difficile Infection: Focused on patients suffering from recurring Clostridium difficile infections, IMM-529 is under development, showcasing Immuron's commitment towards offering solutions for challenging and recurrent infections.

Through its innovative research and development, Immuron Limited stands at the forefront of creating solutions that promise a healthier future, especially for travelers and individuals suffering from gastrointestinal disorders.